Cocrystal Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2830 www.cocrystalpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma, Inc.

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - Aug 3rd, 2026 5:00 am
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - Jun 3rd, 2026 5:00 am
COCP: Presentation Highlights CDI-988 - Jun 1st, 2026 5:35 am
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - May 26th, 2026 6:00 am
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - May 15th, 2026 6:00 am
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - Apr 30th, 2026 2:05 pm
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention - Apr 7th, 2026 9:27 am
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Apr 4th, 2026 6:57 am
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - Apr 2nd, 2026 6:00 am
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Mar 31st, 2026 6:00 am
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment - Mar 9th, 2026 6:00 am
COCP: CDI-988 Data to be Presented at ICAR 2026 - Feb 23rd, 2026 5:31 am
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 - Feb 19th, 2026 6:00 am
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus - Dec 18th, 2025 6:00 am
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference - Dec 1st, 2025 6:00 am
COCP: Phase 1b Norovirus Challenge Study of CDI-988 to Commence in 1Q26… - Nov 18th, 2025 4:21 am
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - Nov 14th, 2025 6:00 am
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules - Oct 30th, 2025 6:00 am
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program - Oct 27th, 2025 6:00 am
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference - Oct 2nd, 2025 6:00 am